November 2018 - First Report Managed Care

Issue 11
November 2018


According to a recent study presented at AMCP Nexus 2018, providing transparent cost information to prescribers resulted in a positive impact on prescribing trends, and researchers found that prescribers were willing to make retroactive conversions when there was a clear cost benefit.  | Read More
Despite their high price tag, CAR-T regimens were found to be cost-effective compared with other recently approved novel anticancer regimens, according to recent research presented at AMCP Nexus 2018.  | Read More
Outcomes-based contracting (OBC) is gaining traction as a tactic to reduce high drug costs, according to a recent study presented at AMCP Nexus 2018. | Read More
According to the findings, where were presented at AMCP Nexus 2018, generic substitution (GS) and step-therapy (ST) were top concerns for payers, while manufacturer-sponsored drug coupons or copay cards (CB) and pricing transparency (PT) legislation were less familiar with payers. | Read More